Clinical Trial

Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study

Study acronym: SIGNAL
Enrolling by Invitation Phase 4
View on ClinicalTrials.gov →
Summary
Title: Body fluid proteome SIGnatures for persoNALised intervention to prevent cardiovascular and renal complications in diabetes. Aim: To explore the feasibility of using urinary proteomic risk scores in clinical practice to identify patients at risk of developing end organ damage and identify which patients should receive additional renocardiovascular protective treatment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-23.
Status change: Not Yet Recruiting → Enrolling by Invitation 2025-12-15
Trial Details
NCT Number NCT06954090
Lead Sponsor Steno Diabetes Center Copenhagen
Collaborators: Mosaiques Diagnostics GmbH
Conditions Type 2 DM, Type 2 DM /Diabetic Nephropathy, Albuminuria
Enrollment 50 participants
Start Date 2025-11-20
Primary Completion 2026-11-30 (estimated)
Study Completion 2027-05-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-22